Capricor Therapeutics Inc
Here’s whether Capricor Therapeutics Inc (CAPR) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-20.76% over 10 days); RSI 17 — oversold; weak 1-year return of -19.9%; 3-month momentum negative (-77.7%); rising volume on a downtrend (distribution, 1.53x avg). Currently 83.5% off its 52-week high. Score: -7/7.
CAPR is trading below its 200-day MA ($23.18) — a key warning sign the longer-term trend is under pressure. An RSI of 17.1 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of -19.9% compares to +20.4% for SPY (trailed the market by 40.3%). The current 83.5% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.